Author:
Anikeeva O. Yu.,Tevs K. S,Pashkovskaya O. A,Samoylova E. A
Abstract
The results of 2 years survival after stereotactic radiation therapy for 117 patients with early-stages of non-small cell lung cancer (NSCLC) in patients with the age-related contraindications to surgery (with heavy cardiovascular diseases) were analyzed. We compare three treatment methods: 3D conformal radiotherapy in the free breathing - 39 patients (group 1); 3D dynamic conformal radiotherapy with active breath control - 42 patients (group 2), and high-hypofractionated stereotactic radiation therapy - 36 patients (3 group). Local control rate was highest in the group 3 - 85 %. Two year survival rate in groups 1, 2 and 3 reached 41%, 56% and 66 %, respectively. It was revealed that the results of high-dose hypofractionated radiation therapy for 2-year survival rates are comparable with surgery. Thus, the distant stereotactic conformal radiation therapy of NSCLC stages 1 and 2 with active breath control showed a higher efficiency without increasing the toxicity on the mediastinum, which has compromised heavy competing cardiovascular diseases. Also, the best long-term results of treatment were registered in a group of high-dose hypofractionated stereotactic radiotherapy.
Reference25 articles.
1. Пасов В.В., Зубова Н.Д., Иволгин Е.М. Поздние лучевые повреждения органов грудной клетки. Сибирский онкологический журнал. 2009; 6(36): 58-61.
2. Bezjak A., Bradley J., Gaspar L., Timmerman R.D., Papiez L., Gore E. et al. Seamless phase I/II study of stereotactic lung radiotherapy (SBRT) for early stage, centrally located, non-small cell lung cancer (NSCLC) in medically inoperable patients. Radiation Therapy Oncology Group 0813. (Accessed at http://www.rtog.org)
3. Хирургия далеко зашедших и осложненных форм рака легкого. Бисенков Л.Н., Барчук А.С., Бояркин Г.М. и др. СПб: Деан, 2006.
4. Charlson M.E/, Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic co morbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40: 373-83.
5. Fenwick J.D., Nahum A.E., Malik Z.I., Eswar C.V., Hatton M.Q., Laurence V.M. et al. Escalation and intensification of radiotherapy for Stage III non-small cell lung cancer: opportunities for-treatment improvement. Clin. Oncol. 2009; 21(4): 343-60.